LAVA Therapeutics’ $83 Million Series C Financing

Osborne Clarke advised LAVA Therapeutics on the deal.

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, closed a $83 million (€71 million) Series C financing to advance Novel Immuno-Oncology Programs.

The financing was co-led by new investors Novo Ventures and Sanofi Ventures, and included additional new investors Redmile Group, Ysios Capital and BB Pureos Bioventures. In addition, current investors Versant, Gilde Healthcare and MRL Ventures Fund, LLC participated significantly in the round.

The Osborne Clarke in Amsterdam team was led by Partner Herke van Hulst (Picture) and included Senior Associate Geoffrey Beurskens, Partner Cars-Jan van Gool (Civil-Law Notary), Associate Arlette Vrolijk (Candidate Civil-Law Notary) and Associate Florien Sanders (Corporate M&A).

Involved fees earner: Geoffrey Beurskens – Osborne Clarke; Florien Sanders – Osborne Clarke; Cars-Jan van Gool – Osborne Clarke; Herke van Hulst – Osborne Clarke; Arlette Vrolijk – Osborne Clarke;

Law Firms: Osborne Clarke;

Clients: LAVA Therapeutics;